Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Olaflur→

Olaflur Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
6818-37-7
Molecular formula
C27H60F2N2O3
Molecular weight
498.8 g/mol
Drug class
Organic amine fluoridetopical anticaries agent
Mechanism of action
Provides fluoride ions that promote remineralisation of enamel, increase resistance to acid dissolution and reduce bacterial acid production in dental biofilm. The amine-containing formulation supports local retention of fluoride on tooth surfaces.
Indications / reported uses
  • Prevention of dental caries and reduction of dentin hypersensitivity with authorised topical dental preparations such as gels, rinses or toothpaste; exact claims depend on fluoride concentration and product authorisation

Sources: NLM MeSH — Olaflur · PubMed — Amine fluoride / olaflur dental prevention · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Olaflur Environmental Risk Assessment (ERA) (the Olaflur ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.